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Abstract 
Vaccinia virus (VACV) is a large double-stranded DNA virus and the 
prototypical member of the family Poxviridae and is most notable for its use as 
the vaccine that eradicated smallpox (variola virus). More recently, VACV has 
been used to develop recombinant vaccines and immunotherapies. However, 
many of these processes require VACV replication to be tightly controlled. RNA 
interference (RNAi) is a powerful tool for in vitro silencing of mRNAs that are 
complimentary to 19-21 base pairs (bp) of double-stranded RNA (dsRNA). This 
project outlines the design and preliminary analysis of two inducible RNAi 
silencing constructs targeting multiple VACV essential genes during VACV 
replication. The two designs include one multihairpin structure expressing 
multiple shRNAs separated by 6 bp spacers and one head-to-tail design with 
multiple shRNAs separated by 6 bp loops. Plasmids pKJ252 and pKJ253 
(containing the two respective RNAi construct designs, designed such that their 
transcription can be controlled by tet operon elements) were transfected into BS-
C-1 cells previously infected with VACV to generate two new recombinant 
VACVs. The newly generated recombinant VACVs were analyzed via plaque 
assays. Results suggest that one of the designed RNAi silencing constructs 
(multihairpin), when induced with tetracyclines, shows a statistically significant 
decrease in plaque size, indicating reduced VACV replication.   
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Introduction 
 
Vaccinia Virus 
Vaccinia virus (VACV) is the prototype member of the family Poxviridae. In 
1796, Edward Jenner introduced the idea of vaccination by inoculating 
individuals with vesicular fluid of cowpox pustules to provide immunity against 
smallpox. Over time, VACV replaced cowpox virus as the vaccine against 
smallpox and eventually led to the eradication of smallpox in 1980 by the World 
Health Organization (Yilma, 1994). Currently, VACV vectors can be engineered 
to express heterologous viral or non-viral antigens (human and animal vaccines) 
or therapeutic proteins (immunotherapies), or to selectively infect and cause lysis 
in cancer cells (oncolytic therapies). VACV has been widely used as a vector 
because it is thermally stable, easy to propagate, has a broad tropism for 
mammalian cells, and is able to elicit strong humoral and cell-mediated immune 
responses (Verardi et al., 2012).  
VACV is a large double-stranded DNA virus with a linear genome 200 
kilobases (kb) in length that encodes about 200 genes (Smith & Moss, 1983). Its 
genome is packaged in an enveloped virion containing its own transcriptional 
enzymes and machinery, allowing VACV to replicate exclusively in the cytoplasm 
of host cells (Smith & Moss, 1983). The genome of VACV is capable of 
accommodating up to 25 kb of foreign DNA (Smith & Moss, 1983), which makes 
recombinant VACVs (rVACVs) ideal vectors to stably express different genes of 
interest (GoI) to high levels (if desired) in mammalian cells.  
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RNA Interference 
RNA interference (RNAi) is a RNA-dependent gene silencing process in 
which the expression of a gene can be silenced post-transcriptionally by 
interaction with double-stranded RNA (dsRNA). This pathway is naturally found 
in many eukaryotes and is thought to be a cellular defense mechanism against 
dsRNA viruses. In research, RNAi can be used to knock out expression of a GoI 
with high selectivity and specificity (Rao, Vorhies, Senzer, & Nemunaitis, 2009). 
Currently, RNAi is a commonly used tool in vitro and in vivo to silence gene 
expression (Zamore, Tuschl, Sharp, & Bartel, 2000). The two most common 
applications to mediate the RNAi effect involve small interfering RNA (siRNA) 
and short hairpin RNA (shRNA). siRNA is a class of dsRNA molecule that is 
capable of knocking down expression of specific GoIs via the RNAi pathway. On 
the other hand, shRNA is another class of dsRNA with a hairpin turn that also 
can be used to silence gene expression (Rao et al., 2009). Double-stranded 
siRNAs are typically 19 - 21 bp and produced when dsRNA or shRNA encounter 
the cellular enzyme Dicer in the cytoplasm. The resulting siRNA will then bind to 
the enzymatic portion of the RNA-induced silencing complex (RISC) and lead to 
the cleavage of mRNA that is complementary to the siRNA (Rao et al., 2009). 
Thus, RNAi is a powerful mechanism for silencing host and even viral genes. 
Since VACV replication occurs exclusively in the host cell cytoplasm (Smith et 
al., 1983), RNAi can be utilized to target genes that are essential to VACV 
replication. Viral siRNA constructs have been previously shown to inhibit 
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monkeypox virus (another virus that belongs to the Poxviridae family) replication 
by 65-95% in vitro (Alkhalil et al., 2009). Additionally, siRNAs that target several 
essential VACV genes (including B1R, D5R, and G7L) have been shown to 
inhibit VACV replication when each siRNA was introduced individually (Vigne et 
al., 2008). This suggests that VACV replication is sensitive to RNA silencing.  
The use of siRNA as a mediator requires it to be introduced exogenously 
via transfection or other injection methods while an shRNA approach requires a 
transient expression, usually through a viral vector (McIntyre et al., 2011). The 
advantage of using siRNA-mediated RNAi is that the siRNA will interact directly 
with RISC without the need for the dsRNA to be processed by Dicer. siRNAs are 
chemically synthesized and easier to modify as well (Rao et al., 2009). 
Concentrations for effective siRNA-mediated gene knockdown are usually in low 
nM ranges. However siRNA-mediated RNA interference has a shorter duration 
than shRNA. Fluorescent-tagged siRNA exhibits high degradation after reaching 
its 24 hour peak for silencing and RNAi diminishes within 48 hours (Rao et al., 
2009).  
RNAi mediated by shRNA is usually vector-based and relies on the host’s 
transcription machinery. When compared to siRNA, only low copy numbers (as 
low as 5) of shRNA are sufficient to provide a continuous gene knockdown effect 
since shRNA is constitutively synthesized in the host (Rao et al., 2009). More 
importantly, vector-based shRNA expression can also be regulated or induced by 
manipulating the expression strategy, such as altering the promoter or 
redesigning the shRNA structure (Rao et al., 2009). Additional studies have 
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shown that a net suppressive activity can be maintained from multiple 
simultaneous acting shRNAs (McIntyre et al., 2011). For example, studies 
regarding a combinatorial RNAi approach involving the expression of multiple 
shRNA combinations renders a near-complete coverage of all HIV-1 strains, 
providing a potential novel therapy that is protective against current strains of HIV 
(McIntyre et al., 2011). This means a combinatorial RNAi approach with multiple 
gene targets could potentially be used in knocking down expression of VACV 
essential genes with higher efficiency when compared to targeting one gene at a 
time.  
 
 
Selecting Targets for RNAi  
A number of different RNAi targets and strategies for the inducible 
silencing of VACV replication were identified through literature review. Three 
VACV late essential genes were chosen based on previous inhibition efficiency. 
Several siRNA sequences targeting the VACV late essential gene D5R have 
been shown to lead to 90% decreased viral replication when transfected at 100 
nM and exhibit a prolonged antiviral effect for up to 72 hours (Vigne et al., 2008). 
One of the sequences had up to 93.2% inhibition of VACV replication at 100 nM 
while two others had 86.9% and 90.2% inhibition of replication at 100 nM, 
respectively (Vigne et al., 2008). Another siRNA targeting a late essential gene, 
G7L, has been shown to reduce VACV replication by 97% at 100 nM (Vigne et 
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al., 2009). A third siRNA targeting the late essential gene E8L (equivalent to D8L 
in VACV) in monkeypox virus has shown 95% inhibition efficiency in viral 
replication (Alkhalil et al., 2009). The D5R gene encodes the D5 protein, a DNA-
independent nucleoside triphosphatase that is essential for viral DNA replication, 
and is highly conserved in the Orthopoxvirus genus (Vigne et al., 2008). The E8L 
gene encodes the E8 protein, which plays an important role in cell attachment 
and viral entry (Alkhalil et al., 2009). Knockdown of this gene has been shown to 
cause reduction in plaque numbers (Alkhalil et al., 2009). Another gene G7L 
encodes the G7 protein, which is required for virus morphogenesis (Vigne et al., 
2009).  
 
Tetracycline and Lactose Operons 
Expression of RNAi silencing must be tightly controlled and only 
expressed when inhibition of VACV is necessary. Therefore RNAi silencing 
should be incorporated in a system where its expression could be turned on in 
the presence of a “switch” -- an inducer. 
The tetracycline (tet) operon is a bacterial gene expression regulatory 
sequence discovered in Escherichia coli, which plays a role in bacterial 
resistance against tetracycline antibiotics. The operon sequence consists of the 
tetA resistance gene and the tetR repressor gene. In the absence of 
tetracyclines, such as doxycycline (DOX), the repressor protein TetR binds to the 
tetO2 operator sequence, thus inhibiting the transcription of tetA (Hillen & Berens, 
12 
 
1994). When tetracyclines are present, TetR binds to tetracyclines and 
undergoes a conformational change, which prevents TetR from binding to the 
operator, allowing the transcription of the tet operon genes (Hillen & Berens, 
1994). The tet operon has been utilized in VACV and has been used to regulate 
the expression of genes essential to VACV replication. In current tetracycline-
based replication-inducible and replication-repressible VACVs in the Verardi 
Laboratory, only expression of late genes can be tightly regulated (Verardi et al. 
2013).  
The lactose (lac) operon is another bacterial gene regulatory sequence 
that has also been used extensively in research. The lac operon contains a 
promoter, terminator, regulator, operator, and three structural genes (Lewis, 
2005). The three structural genes lacZ, lacY and lacA encode the proteins β-
galactosidase, a permease, and a transferase respectively. These structural 
genes are located downstream of the operator sequence lacO to which the lac 
repressor LacI binds (Lewis, 2005). When LacI binds to the operator, 
transcription of the three structural genes is inhibited. In the presence of 
allolactose inducers (e.g. isopropyl-β-D-thiogalactoside, IPTG, an allolactose 
analog), LacI binds to the inducer and transcription of the structural genes occurs 
(Lewis, 2005). 
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Hypothesis 
If we can incorporate RNAi silencing of a VACV essential gene into an 
inducible system, we could control VACV replication with the addition (or 
removal) of an inducer that allows transcription of a RNAi construct and prevent 
VACV replication through RNAi. It is necessary to have the RNAi silencing 
mechanism be inducible in order to selectively halt VACV replication. For 
example, when generating a rVACV, replication of the parental strain must be 
restricted in order to purify the rVACV. This inducible system will utilize tet 
operon elements and therefore can be controlled with the addition or removal of 
tetracyclines. However, only late VACV essential genes can be regulated by the 
current inducible system (Weber et al., 2007), therefore only late VACV essential 
genes will be targeted for inducible silencing, with preference to those for which 
siRNA target sequences have been previously validated by other studies.  
The goal of this project is to design and characterize the efficiency of an 
inducible RNAi silencing mechanism controlling the expression of VACV 
essential genes. This will be done by creating a rVACV that incorporates features 
based on previous designs and studies that involve shRNA-mediated RNAi 
expression (Lee et al., 2012; McIntyre et al., 2011). In dsRNA, the sense strand 
is the strand of RNA that has the same sequence as the matching mRNA. In 
order to achieve the highest efficiency of gene silencing, five different sense 
strands along with their antisense strands targeting three late essential genes 
were chosen based on high RNAi silencing efficiency in previous studies (Alkhalil 
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et al., 2009; Vigne et al., 2008, 2009). Two different RNAi constructs were 
designed to carry out expression of multiple shRNAs when transcribed.  These 
constructs were placed under the control of a strong VACV late promoter and tet 
operator sequence to allow high amounts of RNAi expression to be induced with 
the addition of a tetracycline inducer such as DOX. A plasmid was generated for 
homologous recombination with the parental VACV to generate a new rVACV. A 
reporter gene was included to distinguish the new rVACV from the parental strain 
during the purification process. In the absence of inducer, TetR will be expressed 
and bind to tetO2, preventing the expression of the RNAi construct.  In the 
presence of DOX, TetR will bind to the inducer and undergo a conformational 
change, decreasing its affinity for the tetO2 operator sequence. The RNAi 
construct is transcribed and should halt the expression of the targeted VACV 
essential genes, thus preventing VACV replication (Figure 1). 
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Materials and Methods 
Identification of Target Genes 
Only genes that have been shown to be sensitive to RNAi-mediated gene 
silencing were selected, with the preference of sense strands that have a high 
inhibition efficiency (i.e. decrease of viral replication by 90% or greater). Only 
sequences of late VACV genes were selected. Five sense strands from siRNA 
sequences that target D5R, D8L, and G7L (Table 1) that were shown to be 
effective were chosen from literature and were incorporated into the RNAi 
construct as shRNAs instead of siRNAs with the addition of a 4 bp loop in each 
hairpin.  
 
Design of RNAi Construct Plasmids 
After identifying target genes and sense strand sequences, two RNAi 
constructs were designed and synthesized into a vector backbone such that 
transcription of the construct would result in multiple shRNAs. One design 
incorporated a multi-hairpin structure, similar to a RNAi-microsponge structure 
decribed by Lee et al. (2012), where multiple shRNA repeats are transcribed 
from a single plasmid. The five shRNAs that target the essential genes are linked 
together starting from the sense strand of one shRNA followed by a 4 bp loop 
and the antisense strand of the shRNA, followed by a dTdT overhang and a 6 bp 
spacer between the first shRNA and the next shRNA (Figure 2A). Another design 
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incorporated a head-to-tail structure described by McIntyre, et al. (2011) which 
involves the linking of all five sense strands separated by a 6 bp spacer, a 4 bp 
end loop, and all five antisense strands corresponding with the sense strands 
(Figure 2B).  
In the multi-hairpin construct, two unique restriction enzyme sites were 
incorporated in the spacer to allow the possibility of subcloning a plasmid with 
only a single shRNA construct by removing the remaining 4 shRNAs after 
restriction enzyme digest to compare single-shRNA and multi-shRNA efficiency. 
Two restriction enzymes were added on 2 sites on both ends of the construct for 
future digestion, isolation and subcloning. In both designs, the RNAi constructs 
were placed under the control of the strong VACV late promoter P11 and the 
tetO2 operator sequence to drive high expression in the presence of DOX. The 
two constructs were then synthesized into plasmids by a third party vendor (DNA 
2.0, Menlo Park, CA.) The natural promoter for D6R was also included in the 
synthesized construct to simplify and reduce the steps of cloning. Vector pKJ241 
was synthesized with the multi-hairpin RNAi construct shG7L1-shD8L1-shD5R3-
shD5R1-shD5R2. Vector pKJ242 was synthesized with the head-to-tail RNAi 
construct shD8L1-shD5R3-shD5R1-shD5R2-shG7L1. A proposed secondary 
structure of the transcribed RNAi constructs is shown in Figure 3 using a web 
server for RNA secondary structure prediction developed by Reuter et al., 2010.   
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Plasmid Construction and Gene Cloning  
As an overview, RNAi constructs with compatible sticky ends were 
synthesized and then cloned into the backbone derived from pBJ207, an existing 
plasmid in the Verardi laboratory that contains a kanamycin resistance gene, tet 
operon elements, including tetR placed under the control of a strong constitutive 
promoter PE/L, to control transcription of the VACV D6R gene, a fluorescent 
reporter gene EGFP, and two flanking regions that are homologous to the VACV 
D5R and D6R genes along with the natural promoter for D6R. The two 
homologous regions flanking the construct allow the possibility of homologous 
recombination with a parental VACV to generate a new rVACV, which could be 
screened using the fluorescent reporter gene EGFP (Figure 4).  
pKJ241 and pKJ242 were double-digested with EagI-HF and SphI-HF to 
create compatible sticky ends to ligate into the pBJ207-derived backbone. The 
two restriction enzymes used allow the placement of the RNAi constructs without 
removing any genetic elements from pBJ207. The vector derived from pBJ207 
was also dephosphorylated with Antarctic Phosphatase under appropriate 
incubating conditions in order to ensure that the vector does not re-circularize 
during ligation. Inserts and vectors were then ligated together with T4 DNA ligase 
and electroporated into NEB 5 α-electrocompetent Escherichia coli using the 
Gene Pulser Xcell Electroporation System from Bio-Rad (Hercules, CA) to create 
pKJ252 (Figure 5A) and pKJ253 (Figure 5B), respectively. The transformed 
E.coli were then plated on LB agar with 50μg/ml kanamycin and incubated at 
37oC overnight for 16 hours. Isolated colonies were amplified and the plasmids 
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were isolated. Plasmids obtained were verified by restriction enzyme digestions 
and viewed on an electrophoresis gel containing ethidium bromide under UV 
light. After confirming the identity of the plasmid, one isolated colony containing 
the correct plasmid was then further amplified by growing the transformed E.coli 
in LB containing kanamycin. The amplified plasmids were then isolated and 
purified using a commercial NucleoSpin® Plasmid kit (Macherey-Nagel, Inc., 
Bethlehem, PA). After a pure stock of each plasmid was obtained, restriction 
enzyme digests were performed to again verify the identity of the plasmid. All 
enzymes and cells used were obtained from New England Bio Labs (Ipswich, 
MA.) 
 
Mammalian Cell Culture 
African Green Monkey kidney epithelial cells (BS-C-1) were grown in 
Dulbecco’s modified Eagle medium (DMEM) supplemented with amino acids and 
glucose (cDME; Invitrogen, Grand Island, NY) with 10% tetracycline-tested fetal 
bovine serum (FBS; Atlanta Biologicals, Lawrenceville, GA). Cells were 
incubated at 37oC with 5% CO2. 
 
Viruses 
The IPTG-inducible virus viD6RlacR was used as the parental strain. It 
contains the inducible elements of the lac operon and has been amplified, 
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purified and titered by the Verardi laboratory. The lacO operator is placed 
downstream of the natural D6R promoter, which functions similarly to the tet 
operator but instead with the inducer IPTG that binds to the repressor LacI. It 
also contains a fluorescent reporter gene DsRed under the control of the 
synthetic VACV promoter PE/L. This construct has been placed between the D5R 
and D6R genes, which allows the transcription of the VACV essential gene D6R 
and therefore replication of the virus in the presence of IPTG. viD6RlacR was 
chosen as the parental strain to create a new rVACV because it is replication-
inducible in the presence of IPTG and contains a selection marker distinctive 
from the selection marker of the new rVACV containing the RNAi constructs that 
allows selection to be more straightforward. The IPTG-inducible system in 
viD6RlacR is also flanked by the D5R and D6R genes, which allows homologous 
recombination to occur with pKJ252 or pKJ253 to create new rVACVs to test the 
efficiency of RNAi-mediated gene silencing.  
Recombinants viRNAi-1 and viRNAi-2 were obtained by homologous 
recombination between viD6RlacR and pKJ252 or pKJ253, respectively. BS-C-1 
cells were seeded in 12-well cell culture plates and reached ~95% confluency at 
the time of the experiment. The parental stock viD6RlacR was sonicated four 
times with 30 second bursts and vortexed in between. viD6RlacR was then 
diluted to reach a multiplicity of infection (MOI) of 0.1 for infection. Cells were 
then washed with cDME and overlayed with the diluted virus. Plates were then 
placed on a rocking platform and incubated for 1 hour. 1 hour post infection (hpi) 
cells were washed again and overlayed with cDME supplemented with 2.5% FBS 
20 
 
with or without 100 ng/ml IPTG and transfected with the appropriate plasmids 
using FuGENE HD transfection reagent (Promega, Madison, WI). 2 days post 
infection (dpi), supernatant of the 12-well cell culture plate was then collected, 
centrifuged, and transferred to a 24-well cell culture plate, which was overlayed 
with cDME supplemented by 2.5% FBS without IPTG to prevent the IPTG-
inducible parental strain from growing. 2 dpi, supernatant from single, isolated 
rVACV plaques (indicated by EGFP expression observed under a fluorescence 
microscope) were then collected, centrifuged, diluted and transferred to a new 
24-well cell culture plate. After 4 dpi, wells with single, isolated rVACV were 
screened to see if any parental virus was still present. Plaques with no indication 
of the parental virus were allowed to grow until 100% cytopathic effect (CPE) was 
reached. Cell lysate and supernatant of the rVACV were then collected. 
  
Infection and Measurement of RNAi Efficiency 
BS-C-1 cells were seeded in 6-well cell culture plates in order to reach 80-
90% confluency at the time of the experiment. viRNAi-1 or viRNAi-2 were 
sonicated four times with 30 second bursts and vortexed in between. The viruses 
were then diluted to achieve ~30 PFU/well. Cells were then washed with cDME 
and infected with the diluted virus. Plates were then placed on a rocking platform 
and incubated for 1 hour. Cells were washed again and overlayed with cDME 
supplemented with 2.5% FBS in the absence or presence of varying 
concentrations of DOX (0.001 μg/ml DOX, 0.01μg/ml DOX, 0.1 μg/ml DOX, 1 
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μg/ml DOX, or 10 μg/ml DOX). Cells were incubated at 37oC with 5% CO2. 2 dpi 
plates were stained and fixed with 0.5% crystal violet/20% ethanol. Individual 
plaques were imaged with an inverted microscope and representative plaques 
were analyzed using measure software (AxioVision, 4.8.1, Carl Zeiss). The mean 
plaque radius was calculated in different concentrations of DOX with a 95% 
standard error of the mean (SEM) and statistical significance was determined 
using a t-test comparing different concentrations of DOX to the absence of DOX 
usinf GraphPad Prism v. 6.0f (GraphPad Software, La Jolla, CA).  
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Results 
Results obtained by the experiments described above are considered 
preliminary because only one plaque assay was performed for viRNAi-1 and two 
were performed for viRNAi-2 without obtaining the titer of each recombinant due 
to time constraints. All calculations for the amount of virus used in infections were 
estimations based on previous observations in plaque assays in the Verardi 
laboratory. viRNAi-2 was tested first for its efficiency in RNAi silencing since its 
recombinants were first obtained and amplified.  
In the first plaque assay, BS-C-1 cells were infected with viRNAi-2 at 
~30PFU/well based on an estimated titer of 107 PFU/ml in the absence or 
presence of either 0.001 μg/ml DOX, 0.01 μg/ml DOX, 0.1 μg/ml DOX, or 1 μg/ml 
DOX (Figure 6). About 15 PFUs were obtained in each well. No distinguishable 
difference in plaque number or size was observed with the naked eye even at the 
highest concentration of DOX. Therefore in the second plaque assay, DOX 
concentration was increased 10 fold to 10 μg/ml and the amount of viRNAi-2 
used to infect the cell culture was doubled. Appropriate concentrations of DOX 
were also added during the 1 hour infection phase of the experiment in the hope 
to prevent any potential leaky expression of the targeted late essential genes. 
The same DOX concentrations and calculations to obtain ~30 PFU/well were 
applied to viRNAi-1 as well once it was obtained and amplified. 
After the second plaque assay, about 40 PFU were obtained in each well 
infected by viRNAi-1 with an observable difference in plaque size between 10 
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μg/ml DOX and no DOX (Figure 7A). About 20 PFU were obtained in each well 
infected by viRNAi-2. However, there was still no distinguishable difference 
observed in plaque number or size in cells infected by viRNAi-2, despite the 
increase in DOX concentration (Figure 7B). Therefore plaque size (radius) was 
only measured for viRNAi-1 under an inverted microscope (AxioVision, 4.8.1, 
Carl Zeiss) and analyzed for any statistical significance using GraphPad Prism v. 
6.0f (GraphPad Software, La Jolla, CA). 
The radius of plaques formed in the presence of DOX were 
distinguishable from plaques formed in the absence of DOX (Figure 8). In the 
presence of 1 μg/ml DOX there was a small but statistically significant difference 
(P < 0.05) between the sizes of plaques formed in the presence of 1 µg/ml DOX, 
compared to plaques formed in the absence of DOX. The average radius 
decreased by about 40 μm with the addition of 1 μg/ml DOX. A greater difference 
(P < 0.0001) was observed when comparing plaque sizes of no DOX versus 10 
μg/ml DOX. Average plaque radius decreased by about 160 μm, an approximate 
16% decrease in plaque size. This suggests that viRNAi-1 replication was 
inhibited with the increase of DOX concentrations while viRNAi-2 replication was 
unaffected. Taken together, it also suggests that a multihairpin RNAi design may 
be more effective than a head-to-tail RNAi design.     
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Discussion 
In these preliminary experiments, we were not able to demonstrate 
efficient silencing of VACV essential genes through induced RNAi expression. In 
plaque assays of viRNAi-2 (head-to-tail), no distinguishable difference in VACV 
replication was observed in the presence or absence of DOX. Although there 
was a statistically significant decrease of viRNAi-1 (multihairpin) plaque sizes in 
the presence of 1 or 10 µg/ml, the decrease in plaque size was not enough to 
completely inhibit VACV replication. Therefore the implementation of this 
construct design may be limited. There is also a need to investigate the 
difference between targeting a single essential gene versus targeting multiple 
essential genes. Targeting multiple genes requires a more complex design and 
therefore may pose a greater number of genetic hurdles to overcome before the 
sense strand of the targeted sequence could be delivered to RISC and initiate 
the RNAi process. There is also the potential that the construct may have 
mutated either during the cloning or rVACV purification process. Sequencing may 
be required to confirm the identity of the plasmid before the infection/transfection 
process. It would have also been ideal if the titer of each recombinant was 
obtained before performing the plaque assay instead of relying on titer 
estimations. 
Better implementation of inducible RNAi silencing of VACV essential 
genes may require construct designs that are more efficient. In this set of 
experiments, late essential genes were selected as targets. In other studies 
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(Vigne et al., 2009), early essential gene targets were also identified and have 
been shown to decrease VACV replication to 90% or higher. In this study, we 
used the tet repressor to control construct expression because it has been 
thoroughly characterized in VACV already. If both early and late essential genes 
could be targeted simultaneously, we may reduce VACV replication to a greater 
extent. The multihairpin design was derived from a multi-shRNA expression 
system that required multiple repeats of the same shRNA (Lee et al., 2012). In 
this study, different shRNAs that targeted multiple essential genes were used to 
form the multihairpin structure rather than the same shRNA, which only targets 
one gene at a time.  
Eventually, successful designs could be implemented to control 
expression of GoIs in VACV for different purposes. For example, VACVs could 
be engineered to turn off essential genes for VACV replication upon addition of 
tetracyclines in response to adverse reactions in rVACV vaccines. Another 
potential implementation of induced RNAi silencing of VACV essential genes 
may include a more efficient way to generate rVACVs. The typical way to 
generate rVACVs is by transfecting cells infected with a parental VACV strain 
with a plasmid containing a desired genetic region flanked by sequences 
identical to the VACV genome (Falkner & Moss, 1990). Homologous 
recombination can occur between the identical sequences in the plasmid and 
parental VACV, resulting in the insertion of the desired genetic region into the 
VACV genome (Falkner & Moss, 1990). These infrequently-generated rVACVs 
must then be purified from the parental VACV, which usually takes months to 
26 
 
complete using the traditional transient dominant selection process (Falkner & 
Moss, 1990). If we can control VACV replication through RNAi during the 
purification process of creating an rVACV, the parental VACV can be rapidly 
eliminated from the parental/recombinant pool through silencing of essential 
VACV genes. This way we could purify rVACV in a much more efficient manner.  
Although we have developed a prototype for inducible RNAi silencing for 
VACV, we did not succeed in inhibiting VACV replication to the extent where 
meaningful implementations could be applied. Time constraint was also another 
factor that prohibited further testing and troubleshooting for each construct and 
the possibility of including more RNAi construct designs for analysis. In the 
future, development of a more efficient inducible RNAi system would allow for 
better utility in VACV research.  
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Figure 1. Inducible RNAi mechanism. A: In the absence of DOX, TetR binds to 
the tetO2 operator sequence. The RNAi construct is not transcribed and VACV 
replicates normally. B: In the presence of DOX, TetR binds to DOX and 
undergoes a conformational change. RNAi is transcribed and silences VACV 
essential genes, which prevents VACV replication. 
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Table 1. Sense strands chosen for targeting late essential genes based on 
literature review.  
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Targeted Gene siRNA Sequence (sense, 5’-3’) Source 
D5R siD5R-1 ACTGTTTAATATTGCACAA 
(19nt) 
(Vigne et al., 2008) 
D5R siD5R-2 CACCTTGTGCATTATGTAA 
(19nt) 
(Vigne et al., 2008) 
D5R siD5R-3 CGAACACTATTAGAATTAA 
(19nt) 
(Vigne et al., 2008) 
D8L (E8L in 
MPV) 
siD8L-1 GAATAGCGGTGAGTATAAA 
(19nt) 
(Alkhalil et al., 2009) 
G7L siG7L-1 GCGTCGTTCTACAATTTTT 
(19nt) 
(Vigne et al., 2009) 
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Figure 2. Inducible RNAi Construct Design Sequences. Both RNAi constructs 
were placed under the control of the strong VACV late promoter P11 (dark blue in 
larger font) and the tet operator sequence (green) to drive high expression in the 
presence of DOX. Purple represents the sense strand. Orange represent the 
antisense strand. The 4 bp gray sequence between the purple and orange 
sequences represent the loop. Red represents the dTdT overhang. Arrows 
represent a promoter or shRNA. Restriction enzyme sites are labelled. A: 
Multihairpin construct design containing shG7L1-shD8L1-shD5R3-shD5R1-
shD5R2 (used to generate viRNAi-1). Each shRNA is separated by a 6 bp spacer 
(dark blue in smaller font).  B: Head-to-tail construct design containing shD8L1-
shD5R3-shD5R1-shD5R2-shG7L1 (used to generate viRNAi-2). Different sense 
strands and antisense strands are separated by a 6 bp spacer (gray for sense 
strands, cyan for antisense strands). 
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Figure 3. Proposed secondary structure of transcribed RNAi constructs.  
Structures were generated using RNAstructure: software for RNA secondary 
structure prediction and analysis (Reuter et al., 2010) A: Multihairpin construct 
design (viRNAi-1). B: Head-to-tail construct design (viRNAi-2). 
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Figure 4. Features of pBJ207. Vector backbone for pKJ252 and pKJ253. RNAi 
constructs with compatible sticky ends (SphI and EagI) were inserted into 
pBJ207 by replacing the original sequence containing the D6R promoter and 
tetO2 operator sequence with the sequences described in Figures 2A and 2B to 
generate pKJ252 and pKJ253, respectively. 
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Figure 5. Features of pKJ252 and pKJ253.  Both plasmids contain a 
kanamycin resistance gene, elements of the tet operon to control transcription of 
the RNAi construct, tetR placed under the control of a strong constitutive 
promoter PE/L, and a fluorescent reporter gene EGFP also under PE/L.  A: pKJ252 
contains the multihairpin RNAi construct shG7L1-shD8L1-shD5R3-shD5R1-
shD5R2 (viRNAi-1). B: pKJ253 contains the head-to-tail RNAi construct shG7L1-
shD8L1-shD5R3-shD5R1-shD5R2 (viRNAi-2). 
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Figure 6. Plaque Assay of viRNAi-2 with varying DOX concentrations. BS-C-
1 cells were infected with viRNAi-2 (head-to-tail) at ~30 PFU/well in the absence 
or presence of varying concentrations of DOX. At 48 hpi cells were stained and 
fixed with 0.5% crystal violet/20% ethanol and the entire well was imaged with a 
Samsung Galaxy S5 G900T.  
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               No DOX          + 0.01 μg/ml DOX      +1 μg/ml DOX    
 
 
 
 
 
 
     + 0.001 μg/ml DOX     + 0.1 μg/ml DOX       +1 μg/ml DOX    
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Figure 7. Plaque Assay of viRNAi-1 and viRNAi-2 with varying DOX 
concentrations. BS-C-1 cells were infected with either viRNAi-1 (multihairpin) or 
viRNAi-2 (head-to-tail) at ~30PFU/well in the absence or presence of varying 
concentrations of DOX. At 48 hpi cells were stained and fixed with 0.5% crystal 
violet/20% ethanol and the entire well was imaged with a Samsung Galaxy S5 
G900T.. A: 6-well cell culture plate infected with viRNAi-1; B: 6-well cell culture 
plate infected with viRNAi-2. 
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A.  
              No DOX             + 1 μg/ml DOX      +10 μg/ml DOX 
 
B. 
              No DOX             + 1 μg/ml DOX      +10 μg/ml DOX 
  
  
48 
 
 
 
 
 
 
Figure 8. The effect of DOX on the plaque size (radius) of viRNAi-1 
inducibly expressing the multihairpin RNAi construct. BS-C-1 cell s were 
infected with viRNAi-1 (multihairpin) at ~30 PFU/well in the absence or presence 
of multiple concentrations of DOX. At 48 hpi, cells were stained and fixed with 
0.5% crystal violet/20% ethanol. Representative plaques were imaged under an 
inverted microscope and analyzed with measuring software (AxioVision, 4.8.1, 
Carl Zeiss). The symbol * indicates statistically significant differences (P < 0.05) 
when comparing no DOX vs. 1 μg/ml DOX. The symbol ** indicates statistically 
significant differences (P < 0.0001) when comparing no DOX vs. 10 μg/ml DOX. 
Error bars = SEM.  
49 
 
 
 
 
